AFT-65: ASCENT-05: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Read moreEMBER-4: A Randomized, Open-Label, Phase 3 Study of
Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who
have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+,
HER2- Early Breast Cancer with an Increased Risk of Recurrence
Read moreA Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Read moreA011801 - THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB
Read moreNeurocognitive changes in breast cancer patients on hormonal therapy. Is there a difference between objective and perceived neurocognition?
Read moreMammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)
Read more
